Company: TVRD
Filing Date: 2025-03-24
Form Type: 8-K
Source: 0001104659-25-027233
Chunk: 2

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-03-24
Form: 8-K
Item: Item 8.01
Chunk 2
---
 designated by Tvardi if prior to the closing of the Merger or by the combined company if following the consummation
of the Merger. The Combined Company Board will have an audit committee, a compensation committee and a nominating and corporate governance
committee, in accordance with the rules of Nasdaq. All of Cara’s current directors other thanMs. Shiffare expected
to resign from their positions as directors of Cara, effective upon the Effective Time. For a more complete description of the Combined
Company Board, please see the section titled “ Management Following the Merger” beginning on page 360 of this proxy statement/prospectus.

  The following disclosure replaces the first paragraph under the subsection titled “ Directors  

At the Effective Time, the combined
company is expected to initially have a seven-member board of directors, comprised of five members designated by Tvardi (Sujal Shah, Michael
Wyzga, Wallace Hall, Shaheen Wirk and Imran Alibhai), one member designated by Cara (Susan Shiff)and one vacancy, to be designated
by Tvardi if prior to the closing of the Merger or by the combined company if following the consummation of the Merger, until their respective
successors are duly elected or appointed and qualified or their earlier death, resignation or removal. If the one remaining director is
not identified prior to the Effective Time, the Combined Company Board anticipates reducing the size of the Combined Company Board to
six directors.

  The following new disclosure under a section titled “ Legal Proceedings” is added to page 25                 

Legal Proceedings

Two lawsuits were filed in the Supreme
Court of the State of New York, County of New York on March 5 and March 6, 2025 by two purported stockholders of Cara in connection
with the Merger. The lawsuits are captioned Joseph Clark v. Cara Therapeutics, Inc., et al., No. 651260/2025, or the Clark Complaint,
and Michael Kent v. Cara Therapeutics, Inc., et al., No. 651272/2025, or the Kent Complaint, and together with the Clark Complaint,
the Complaints. Each Complaint named as defendants Cara and the members of the Cara board of directors. The plaintiffs contended that
the Form 424 prospectus filed on February 14, 2025, or the Form 424 Prospectus, omitted or misrepresented material information
regarding the Merger, rendering the Form 424 Prospect